ARTICLE | Product Development
BioCentury’s ASCO wrap includes analysis of Tagrisso, Imfinzi and Jemperli readouts
By Lauren Martz, Executive Director, Biopharma Intelligence
June 7, 2024 10:55 PM UTC
The 2024 ASCO conference has proven just how transformational targeted and immunotherapies can be when they’re applied early in disease. As cancer treatments become more effective and less toxic, moving them up in the treatment paradigm — into entirely new settings for systemic therapies — is putting cures within reach for more patients.
Several of the biggest readouts presented at this year’s American Society of Clinical Oncology (ASCO) conference highlight new opportunities for systemic therapies that didn’t exist before. These are places where patient outcomes can be dramatically improved by preventing disease recurrence or avoiding life-altering surgeries, and where untapped commercial opportunity exists. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652629/astrazeneca-gsk-identify-early-treatment-opportunities-with-big-impact-for-cancer-patients